At 15.1% CAGR, Asia Pacific Bioprocessing Market is Projected to be Worth US$ 16,868.77 Million by 2031, says Business Market Insights

According to Business Market Insights' research, the Asia Pacific bioprocessing market was valued at US$ 5,488.87 million in 2023 and is expected to reach US$ 16,868.77 million by 2031, registering a CAGR of 15.1% from 2023 to 2031. Growing biopharmaceutical industry and increasing prevalences of chronic diseases are among the critical factors attributed to drive the Asia Pacific bioprocessing market growth.

In the biopharmaceutical industry, improved bioprocesses are always in demand to address new regulatory requirements, quality control requirements, and production issues in biological products, cell culture titration, and biosimilar production. In recent years, the biopharmaceutical industry has been growing at an unprecedented pace. Biopharmaceutical companies are spending huge sums in R&D to introduce new molecules with enhanced medical and commercial potency for various therapeutic applications. The acceptance of bioprocessing is gradually increasing due to its wide application in research, development, and manufacturing of biologics and biosimilars. Big pharmaceutical companies and contract research organizations are coming up with new medicines and therapy forms to treat a wide range of indications. Further, a strong demand for biologics and biosimilars to treat chronic diseases is, in turn, driving the growth of the biopharmaceutical industry. The biopharmaceutical industry is one of the most significant contributors to the economy. Besides growing economies, rapid growth is witnessed in the research environment in emerging economies such as Brazil, China, and India. Factors such as increasing biologics approval, growing biosimilar pipeline, rising investment in research activities, and increasing focus on developing affordable biologics are facilitating the growth of the biopharmaceutical industry. Apart from these, increasing approvals in gene and cell therapies are favoring the bioprocessing market growth. The approved gene therapies are Glybera (to treat lipoprotein lipase deficiency) and Strimvelis (to treat ADA-severe combined immunodeficiency). Thus, the factors mentioned above are increasing the demand for the large-scale production of various therapeutics, thereby facilitating the growth of the bioprocessing market.

On the contrary, stringent regulatory policies and limitations associated with bioprocessing hamper the growth of Asia Pacific bioprocessing market.

Based on product, the Asia Pacific bioprocessing market is bifurcated into instruments and consumables & accessories. The instruments segment held 67.2% market share in 2023, amassing US$ 3,688.16 million. It is projected to garner US$ 11,747.33 million by 2031 to register 15.6% CAGR during 2023-2031. Furthermore, the instruments segment is sub segmented into filtration devices, bioreactors, chromatography systems, centrifuge, drying devices, and others. Additionally, the bioreactors subsegment is categorized into pilot scale, full scale, and laboratory scale. Furthermore, the subsegment chromatography systems is segmented into liquid chromatography, gas chromatography, and others. Additionally, the consumables & accessories segment is sub segmented into reagents, cell culture media, chromatography resins, and others.

In terms of scale of operation, the Asia Pacific bioprocessing market is bifurcated into commercial operations and clinical operations. The commercial operations segment held 81.6% share of Asia Pacific bioprocessing market in 2023, amassing US$ 4,480.46 million. It is anticipated to garner US$ 14,177.90 million by 2031 to expand at 15.5% CAGR during 2023-2031.

By process, the Asia Pacific bioprocessing market is bifurcated into downstream bioprocess and upstream bioprocess. The downstream bioprocess aids segment held 59.9% share of Asia Pacific bioprocessing market in 2023, amassing US$ 3,285.13 million. It is projected to garner US$ 10,325.07 million by 2031 to expand at 15.4% CAGR from 2023 to 2031.

Based on application, the Asia Pacific bioprocessing market is categorized into monoclonal antibodies, vaccines, recombinant protein, cell & gene therapy, and others. The monoclonal antibodies segment held 37.9% share of Asia Pacific bioprocessing market in 2023, amassing US$ 2,077.69 million. It is predicted to garner US$ 5,970.23 million by 2031 to expand at 14.1% CAGR between 2023 and 2031.

In terms of end user, the Asia Pacific bioprocessing market is categorized into biopharmaceutical companies, contract manufacturing organization, and others. The biopharmaceutical companies held 52.6% share of Asia Pacific bioprocessing market in 2023, amassing US$ 2,888.42 million. It is estimated to garner US$ 9,012.61 million by 2031 to expand at 15.3% CAGR during 2023-2031.

By country, the Asia Pacific bioprocessing market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that China captured 30.4% share of Asia Pacific bioprocessing market in 2023. It was assessed at US$ 1,667.52 million in 2023 and is likely to hit US$ 5,381.14 million by 2031, registering a CAGR of 15.8% during 2023-2031.

Key players operating in the Asia Pacific bioprocessing market are Getinge AB, Thermo Fisher Scientific Inc, Sartorius AG, Corning Inc, Bio-Rad Laboratories Inc, Merck KGaA, 3M Co, Eppendorf SE, Repligen Corp, Entegris Inc, Agilent Technologies Inc, and Cytiva US LLC, among others.

• In November 2022, The Pioneer Antibody Discovery Platform, a new antibody discovery service created especially to produce best-in-class biologic candidates, was introduced by Bio-rad Laboratories Inc. With its state-of-the-art phage display library comprising over 200 billion distinct sequences and its newly created proprietary SpyDisplay selection method, the Pioneer Platform can find high-affinity antibody candidates. The Pioneer Antibody Library has been refined to identify potential therapeutic candidates.
  
  
• In May 2023, In order to promote the healthcare ecosystem in the area, Merck KGaA and the Ministry of Trade, Industry and Energy (MOTIE) in Daejeon City have signed a non-binding Memorandum of Understanding (MoU) for the establishment of a new Asia-Pacific BioProcessing Center. The proposed bioprocessing plant would enable commercial production for Asia-Pacific biotech and pharmaceutical clients. Through this partnership, the pharmaceutical and biotechnology sector in South Korea will have the chance to advance as the country's leading industry for research and technology.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com